Natalizumab for the treatment of relapsing multiple sclerosis
Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in the pivotal AFFIRM study (N = 942). Natalizumab monotherapy reduced risk of disability progression by 42%–54% and annualized relapse rate by 68% dur...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2008
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721353/ |